Bio-Rad Labs Inc. A Stock
Price
Target price
€281.40
€281.40
-0.070%
-0.2
-0.070%
€366.66
23.08.24 / Tradegate
WKN: 865406 / Symbol: BIO / Name: Bio Rad / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Bio-Rad Labs Inc. A Stock
There is nearly no change for the Bio-Rad Labs Inc. A stock today. Compared to yesterday it only changed by -€0.200.
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Bio-Rad Labs Inc. A.
As a result the target price of 366 € shows a positive potential of 30.06% compared to the current price of 281.4 € for Bio-Rad Labs Inc. A.
Pros and Cons of Bio-Rad Labs Inc. A in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bio-Rad Labs Inc. A vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bio-Rad Labs Inc. A | -0.070% | -5.284% | 0.000% | -20.822% | -4.155% | -58.000% | -5.839% |
| Neogen Corp. | -1.360% | 1.379% | -5.161% | - | - | - | - |
| Merit Medical Systems | 0.610% | 0.000% | 3.774% | 29.921% | 21.324% | 39.831% | 165.743% |
| Haemonetics Corp. | 1.500% | -0.735% | -19.162% | -14.013% | -12.338% | 35.542% | -43.505% |
Comments
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $401.00 price target on the stock.
Show more
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Royal Bank of Canada from $402.00 to $401.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at UBS Group AG from $420.00 to $385.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BIO provided by MarketBeat
